1. Division of Pulmonology, Department of Medicine, University of Cape Town, Cape Town, South Africa;
2. Firestone Institute for Respiratory Health, St. Joseph’s Healthcare and Department of Medicine, Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada;
3. Centre for Lung Health, Vancouver Coastal Health Research Institute, University of British Columbia, Vancouver, British Columbia, Canada;
4. Airway Disease Section, National Heart and Lung Institute, Imperial College London, London, United Kingdom;
5. State Key Laboratory of Respiratory Diseases, Guangzhou Institute of Respiratory Health, First Affiliated Hospital of Guangzhou Medical University, Guangzhou, China;
6. BioPharmaceuticals Research and Development, Late-Stage Development, Respiratory and Immunology, AstraZeneca, Barcelona, Spain;
7. BioPharmaceuticals Research and Development, Late-Stage Development, Respiratory and Immunology, AstraZeneca, Gothenburg, Sweden;
8. BioPharmaceuticals Research and Development, Late-Stage Development, Respiratory and Immunology, AstraZeneca, Gaithersburg, Maryland; and
9. The Woolcock Institute of Medical Research, The University of Sydney, Sydney, Australia